Revolution Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Revolution Medicines, Inc. (Nasdaq: RVMD) announced participation in upcoming investor conferences, with CEO Mark A. Goldsmith set to speak at both events. The 2022 Wells Fargo Healthcare Conference will take place from September 7-9, featuring Goldsmith's fireside chat on September 8 at 3:45 p.m. Eastern. The H.C. Wainwright 24th Annual Global Investment Conference follows from September 12-14, with a chat scheduled for September 12 at 7:00 a.m. Eastern. A webcast of the latter will be available online for 14 days post-event.

REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the 2022 Wells Fargo Healthcare Conference and the H.C. Wainwright 24^th Annual Global Investment Conference.

Details of these events are as follows:

• 2022 Wells Fargo Healthcare Conference
  Conference Date: September 7-9, 2022
  Fireside Chat Time/Date: 3:45 – 4:15 p.m. Eastern on Thursday, September 8, 2022
  Format: In-person conference located at Encore Boston Harbor

• H.C. Wainwright 24^th Annual Global Investment Conference
  Conference Date: September 12-14, 2022
  Fireside Chat Time/Date: 7:00 a.m. Eastern on Monday, September 12, 2022
  Format: Hybrid event (in-person and virtual); webcast available

A webcast of the H.C. Wainwright fireside chat can be accessed at: https://ir.revmed.com/events-and-presentations. An archived replay of the webcast will be available on the investors section of the company’s website for at least 14 days following the event.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS^MULTI) and RMC-6291(KRAS^G12C) are in clinical development. Additional RAS(ON) Inhibitors in development include RMC-9805 (KRAS^G12D) and RMC-8839 (KRAS^G13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

When is Revolution Medicines' participation in the 2022 Wells Fargo Healthcare Conference?

Revolution Medicines will participate in the 2022 Wells Fargo Healthcare Conference from September 7-9, 2022, with Mark A. Goldsmith's fireside chat scheduled for September 8 at 3:45 p.m. Eastern.

What is the schedule for the H.C. Wainwright 24th Annual Global Investment Conference for RVMD?

The H.C. Wainwright 24th Annual Global Investment Conference is scheduled for September 12-14, 2022, with a fireside chat by Mark A. Goldsmith on September 12 at 7:00 a.m. Eastern.

How can I access the webcast of Revolution Medicines' fireside chat?

The webcast of the H.C. Wainwright fireside chat can be accessed via Revolution Medicines' website and will be available for at least 14 days following the event.

What does Revolution Medicines focus on in its research and development?

Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers, with a pipeline that includes RAS(ON) Inhibitors and RAS Companion Inhibitors.